Get the Stockscreener App
19.99
2.09%
0.41
Pre-market:
20.07
0.08
+0.40%
Roivant Sciences Ltd stock is traded at $19.99, with a volume of 7.29M.
It is up +2.09% in the last 24 hours and up +32.12% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$19.58
Open:
$19.61
24h Volume:
7.29M
Relative Volume:
1.00
Market Cap:
$13.65B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
3.5381
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
+9.71%
1M Performance:
+32.12%
6M Performance:
+72.03%
1Y Performance:
+73.07%
1-Day Range:
$19.39
$20.09
1-Week Range:
$18.27
$20.09
52-Week Range:
$8.73
$20.09
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
19.99 | 13.37B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Will Roivant Sciences Ltd. stock gain from government policiesTrend Reversal & Entry and Exit Point Strategies - newser.com
Is Roivant Sciences Ltd. (87S) stock prepared for digital transitionIndex Update & Safe Entry Zone Tips - newser.com
Pier Capital LLC Reduces Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Hits New 52-Week High of $19.66, Up 85% - Markets Mojo
Transcend Capital Advisors LLC Purchases New Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Is Roivant Sciences Ltd. (87S) stock safe for risk averse investorsJuly 2025 Trade Ideas & Fast Exit and Entry Strategy Plans - newser.com
Is Roivant Sciences Ltd. stock recession proofPortfolio Growth Summary & Free Risk Controlled Daily Trade Plans - newser.com
Roivant Sciences (NASDAQ:ROIV) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
Roivant Sciences stock hits all-time high at 18.95 USD By Investing.com - Investing.com Australia
Roivant Sciences Ltd. stock prediction for this weekMarket Trend Review & Weekly Momentum Stock Picks - newser.com
Is Roivant Sciences Ltd. (87S) stock a contrarian opportunityIPO Watch & Safe Capital Preservation Plans - newser.com
Key metrics from Roivant Sciences Ltd.’s quarterly data2025 Technical Patterns & Risk Controlled Swing Alerts - newser.com
Top chart patterns to watch in Roivant Sciences Ltd.July 2025 Selloffs & Technical Entry and Exit Alerts - newser.com
Can Roivant Sciences Ltd. rally from current levelsPortfolio Gains Summary & Safe Entry Zone Identification - newser.com
Can Roivant Sciences Ltd. (87S) stock double in coming yearsJuly 2025 Update & Consistent Profit Alerts - newser.com
How to read the order book for Roivant Sciences Ltd.Trade Volume Summary & Real-Time Buy Zone Alerts - newser.com
Risk vs reward if holding onto Roivant Sciences Ltd.2025 Top Gainers & Verified Entry Point Signals - newser.com
Chart based exit strategy for Roivant Sciences Ltd.July 2025 WrapUp & Daily Profit Focused Stock Screening - newser.com
Why Roivant Sciences Ltd. (87S) stock attracts wealthy investorsJuly 2025 Price Swings & Free Weekly Chart Analysis and Trade Guides - newser.com
Roivant Sciences stock hits all-time high at 18.95 USD - Investing.com
Will Roivant Sciences Ltd. (87S) stock outperform benchmarksBuy Signal & Weekly Setup with ROI Potential - newser.com
Y Intercept Hong Kong Ltd Acquires Shares of 271,903 Roivant Sciences Ltd. $ROIV - MarketBeat
Citigroup Raises Price Target for ROIV, Maintains Buy Rating | R - GuruFocus
Roivant Sciences (ROIV): Evaluating Valuation After Strong Share Price Momentum in Biotech - Yahoo Finance
Citi Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $25 - 富途牛牛
Will Roivant Sciences Ltd. stock reach Wall Street targetsWeekly Earnings Recap & Expert Approved Trade Ideas - newser.com
Will Roivant Sciences Ltd. stock outperform international peers2025 Winners & Losers & Free Technical Pattern Based Buy Signals - fcp.pa.gov.br
Roivant Sciences (NASDAQ:ROIV) Sets New 12-Month HighTime to Buy? - MarketBeat
Can Roivant Sciences Ltd. stock sustain revenue growthPortfolio Return Summary & Fast Moving Market Watchlists - fcp.pa.gov.br
Is Roivant Sciences Ltd. stock attractive for passive investorsPortfolio Profit Report & Community Verified Watchlist Alerts - Fundação Cultural do Pará
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):